Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

STEPHEN M LINDSEY

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1558386839
CMS profile
24643
Location
BATON ROUGE, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$5,743.76

85 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 2; records 51–85 of 85 matching records. This page contains 35 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

STEPHEN M LINDSEY

NPI 1558386839 · CMS profile ID 24643

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

BATON ROUGE, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–85 of 85 matching records. This page contains 35 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1558386839?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
STEPHEN M LINDSEY, NPI 1558386839, CMS profile ID 24643. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–85 of 85 matching records. This page contains 35 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1558386839?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). STEPHEN M LINDSEY, NPI 1558386839, CMS profile ID 24643. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–85 of 85 matching records. This page contains 35 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1558386839?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
STEPHEN M LINDSEY, NPI 1558386839, CMS profile ID 24643, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–85 of 85 matching records. This page contains 35 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1558386839?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

85 matching records · $5,743.76 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 85 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–85 of 85.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $24.5805/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997775081 CMS
Amgen Inc. $12.6104/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020145823 CMS
Amgen Inc. $23.4104/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020682133 CMS
Novartis Pharmaceuticals Corporation $23.9304/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991986893 CMS
PFIZER INC. $777.1004/12/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050706083 CMS
UCB, Inc. $32.8004/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021696215 CMS
PFIZER INC. $2,650.0003/30/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050656353 CMS
ABBVIE INC. $26.2903/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997775079 CMS
Amgen Inc. $18.0103/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020145839 CMS
PFIZER INC. $85.3103/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050686887 CMS
Janssen Scientific Affairs, LLC $34.7603/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988571485 CMS
ABBVIE INC. $3.9603/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997775077 CMS
Novartis Pharmaceuticals Corporation $20.5103/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991986901 CMS
ABBVIE INC. $22.2503/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997775075 CMS
Amgen Inc. $28.6003/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020145835 CMS
Amgen Inc. $125.0003/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020682131 CMS
ABBVIE INC. $5.0303/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997775073 CMS
PFIZER INC. $21.1502/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049131281 CMS
Novartis Pharmaceuticals Corporation $19.4502/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991986897 CMS
GlaxoSmithKline, LLC. $20.2102/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001662903 CMS
ABBVIE INC. $14.6602/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997775071 CMS
ABBVIE INC. $31.1202/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997775069 CMS
Amgen Inc. $13.1502/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020145819 CMS
Aurinia Pharma U.S., Inc. $21.8101/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057740728 CMS
GlaxoSmithKline, LLC. $21.9801/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001662893 CMS
ABBVIE INC. $8.4501/19/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997775059 CMS
ABBVIE INC. $8.4501/19/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997775061 CMS
ABBVIE INC. $8.4501/19/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997775063 CMS
ABBVIE INC. $8.4501/19/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997775065 CMS
ABBVIE INC. $8.4501/19/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997775067 CMS
PFIZER INC. $19.1701/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049319153 CMS
ABBVIE INC. $28.2901/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997775057 CMS
Daiichi Sankyo Inc. $20.8201/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006358345 CMS
ABBVIE INC. $20.6801/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997775053 CMS
ABBVIE INC. $18.5201/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997775055 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $70,439.46 160
PY2020 $10,912.41 41
PY2021 $15,043.31 87
PY2022 $13,676.81 91
PY2023 $5,743.76 85
PY2024 $9,115.05 77
PY2025 $4,599.52 75

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,963,415.46 19
PY2024 Principal investigator $5,743.58 3
PY2023 Principal investigator $26,368.91 4
PY2022 Principal investigator $31,787.59 7
PY2021 Principal investigator $97,422.37 27
PY2020 Principal investigator $120,458.71 54
PY2019 Principal investigator $199,651.98 50

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

19 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $58.30 12/17/2025 Non-covered Recipient Entity
Louisiana State University Health Sciences Center New Orleans
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220735278
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 12/17/2025 Non-covered Recipient Entity
Louisiana State University Health Sciences Center New Orleans
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220735280
Principal investigator 1 Boehringer Ingelheim International GmbH $255.50 12/17/2025 Non-covered Recipient Entity
Louisiana State University Health Sciences Center New Orleans
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220735282
Principal investigator 1 Boehringer Ingelheim International GmbH $65.55 12/17/2025 Non-covered Recipient Entity
Louisiana State University Health Sciences Center New Orleans
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220735284
Principal investigator 1 Boehringer Ingelheim International GmbH $20.28 12/17/2025 Non-covered Recipient Entity
Louisiana State University Health Sciences Center New Orleans
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220735286
Principal investigator 1 Boehringer Ingelheim International GmbH $20.28 12/17/2025 Non-covered Recipient Entity
Louisiana State University Health Sciences Center New Orleans
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220735288
Principal investigator 1 Boehringer Ingelheim International GmbH $20.28 12/17/2025 Non-covered Recipient Entity
Louisiana State University Health Sciences Center New Orleans
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220735290
Principal investigator 1 Boehringer Ingelheim International GmbH $20.28 12/17/2025 Non-covered Recipient Entity
Louisiana State University Health Sciences Center New Orleans
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220735292
Principal investigator 1 Boehringer Ingelheim International GmbH $10.00 12/17/2025 Non-covered Recipient Entity
Louisiana State University Health Sciences Center New Orleans
A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) No dispute reported 06/30/2026 1220735294
Principal investigator 1 PFIZER INC. $2,257.20 12/15/2025 Non-covered Recipient Entity
University Medical Center New Orleans
A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS No dispute reported 06/30/2026 1228736753
Principal investigator 1 Novartis Pharmaceuticals Corporation $132.70 10/08/2025 Non-covered Recipient Entity
LSU MEDICAL CENTER
A randomized, double-blind, parallel group, placebo-controlled, multicenter phase 3 trial to evaluate the efficacy, safety and tolerability of ianalumab on top of standard-of-care therapy in patients with active lupus No dispute reported 06/30/2026 1190305871
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,114.35 10/01/2025 Covered Recipient Teaching Hospital
University Medical Ctr. At New Orlea
A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis No dispute reported 06/30/2026 1190297681
Principal investigator 1 UCB SA $49,821.00 08/20/2025 Non-covered Recipient Entity
LSU HEALTH SCIENCES CENTER
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1246659224
Principal investigator 1 Amgen Inc. $2,859,492.82 05/08/2025 Non-covered Recipient Entity
UNIVERSITY MEDICAL CENTER NEW ORLEANS
A Phase 2a, Open Label, Multicenter, Platform Trial to Assess the Safety, Tolerability, and Efficacy of Inebilizumab and Blinatumomab in Subjects With Autoimmune Diseases No dispute reported 06/30/2026 1246650172
Principal investigator 1 Amgen Inc. $5,612.03 03/31/2025 Covered Recipient Teaching Hospital
University Medical Ctr. At New Orlea
A Phase 2a, Open Label, Multicenter, Platform Trial to Assess the Safety, Tolerability, and Efficacy of Inebilizumab and Blinatumomab in Subjects With Autoimmune Diseases No dispute reported 06/30/2026 1246637556
Principal investigator 1 Novartis Pharmaceuticals Corporation $5,974.32 02/01/2025 Covered Recipient Teaching Hospital
University Medical Ctr. At New Orlea
A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis No dispute reported 06/30/2026 1190295620
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $34,646.72 01/21/2025 Non-covered Recipient Entity
Louisiana State University Health Sciences Center New Orleans
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (POETYK SLE-2) No dispute reported 06/30/2026 1235996153
Principal investigator 1 UCB SA $2,539.06 01/15/2025 Non-covered Recipient Entity
LSU HEALTH SCIENCES CENTER
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1246657267
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,294.85 01/09/2025 Non-covered Recipient Entity
LSU MEDICAL CENTER
A randomized, double-blind, parallel group, placebo-controlled, multicenter phase 3 trial to evaluate the efficacy, safety and tolerability of ianalumab on top of standard-of-care therapy in patients with active lupus No dispute reported 06/30/2026 1190305873